Revision and evaluation of the lung cancer module of the MD Anderson Symptom Inventory / 肿瘤

ABSTRACT

Objective: To revise the lung cancer module of MDASI (MD Anderson Symptom Inventory) and assess the included items and the reliability and validity of the revised lung cancer module. Methods: The original item pool was formulated through literature review, patient interview and expert interview and based on existing instruments measuring multiple cancer symptoms. After two rounds of expert evaluation, the preliminary scale was developed. The reliability, validity and sensitivity were tested among 195 lung cancer patients using the revised lung cancer module combined with MDASI. Results: (1) Feasibility The scale recovery was 100%, the completion rate of the scale was 92.3%, and the time spent on completing this scale was 10-15 min. (2) Reliability The values of Cronbach's alpha of the revised lung cancer module, MDASI and the combined scale were 0.773, 0.914 and 0.922, respectively. (3) Validity The revised 6-item lung cancer module was formulated after two rounds of expert evaluation. The range of content validity index of items was 0.833-1.000. The scale-level content validity index/average was 0.944. The exploratory factor analysis was used to evaluate the construct validity. There was one common factor, which explained for 48.059% of variance. The criterion-related validity was significant (P < 0.01). (4) Sensitivity The scores of the revised lung cancer module were significantly different among the lung cancer patinets by ECOG PS (Eastern Cooperative Oncology Group perfomance status) score (P < 0.01). Conclusion: The revised lung cancer module has good feasibility, reliability, validity and sensitivity. It is appropriate to apply this revised lung cancer module in combination with MDASI to assessment of lung caner-related symptoms in China. Copyright © 2013 by TUMOR.